Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
about
Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.The revival of CpG oligonucleotide-based cancer immunotherapies.
P2860
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@ast
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@en
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@nl
type
label
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@ast
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@en
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@nl
prefLabel
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@ast
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@en
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@nl
P2860
P356
P1433
P1476
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
@en
P2093
Marcin Kortylewski
Ya-Huei Kuo
P2860
P304
P356
10.4161/ONCI.27441
P577
2014-01-03T00:00:00Z